Rheumatoid arthritis

The preparation of a T-cell vaccine takes 10-to-14 days. The inductive course of the treatment consists of 4 weekly subcutaneous immunizations. For consolidating a vaccine effect, immunizations are further fulfilled monthly. The treatment is conducted on an outpatient basis.

The immune-mediated inactivation of self-reactive T lymphocytes results in the inhibition of disease development.

A T-cell vaccine is prepared from patient’s lymphocytes under conditions excluding its contamination with pathogenic infectious agents.

No complications are described.

Autovaccination for rheumatoid arthritis

Rheumatoid arthritis is a disease due to the autoimmune process destructing a articular cartilage. A pivotal role for this process belongs to the proinflammatory T lymphocytes that are self-reactive to cartilage-associated antigens. The standard treatment of rheumatoid arthritis is based on applying medicines (hormones, cytostatic agents and others) with a non-specific (non-selective) immunosuppressive action. Such treatment fails to interrupt entirely the immunopatological events underlying the disease and is associated with serious complications.

The autovaccination-based technology, that has been developed in CICT, is aimed to stimulate patient’s immune reactions directed selectively against the pathogenic, self-reactive Т lymphocytes responsible for disease development (for more information). Clinical improvements of a various extent have been found to be developing in the majority of vaccine-treated patients. Noteworthy is that the benefits from autovaccinotherapy may be observed in the patients not only at the early, but also at late stages of the disease. Autovaccination is safe and well tolerated; no complications were noted.

For more information see the publications.